Non-small-cell lung cancer: how to manage BRAF-mutated disease

Non-small-cell lung cancer: how to manage BRAF-mutated disease

BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes 2 and 3) relies on their biological character...

Full description

Bibliographic Details
Main Authors: Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April AN Rose, Francesco Facchinetti
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2023-05-01
Series:Drugs in Context
Subjects:
braf
dabrafenib
immune-checkpoint inhibitors
nsclc
trametinib
Online Access:https://www.drugsincontext.com/non-small-cell-lung-cancer-how-to-manage-braf-mutated-disease

Internet

https://www.drugsincontext.com/non-small-cell-lung-cancer-how-to-manage-braf-mutated-disease

Similar Items